MY155270A - Use of glp-1 or analogs in treatment of stroke - Google Patents
Use of glp-1 or analogs in treatment of strokeInfo
- Publication number
- MY155270A MY155270A MYPI99004103A MYPI9904103A MY155270A MY 155270 A MY155270 A MY 155270A MY PI99004103 A MYPI99004103 A MY PI99004103A MY PI9904103 A MYPI9904103 A MY PI9904103A MY 155270 A MY155270 A MY 155270A
- Authority
- MY
- Malaysia
- Prior art keywords
- glp
- stroke
- analogs
- treatment
- administered
- Prior art date
Links
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 208000006011 Stroke Diseases 0.000 title 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 3
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Mechanical Light Control Or Optical Switches (AREA)
- Complex Calculations (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10171998P | 1998-09-24 | 1998-09-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY155270A true MY155270A (en) | 2015-09-30 |
Family
ID=22286048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI99004103A MY155270A (en) | 1998-09-24 | 1999-09-21 | Use of glp-1 or analogs in treatment of stroke |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1115421B1 (https=) |
| JP (1) | JP2002526454A (https=) |
| CN (1) | CN1163267C (https=) |
| AT (1) | ATE433324T1 (https=) |
| AU (1) | AU766375B2 (https=) |
| BR (1) | BR9913932A (https=) |
| CA (1) | CA2344056A1 (https=) |
| DE (1) | DE69940975D1 (https=) |
| ES (1) | ES2325777T3 (https=) |
| MY (1) | MY155270A (https=) |
| TW (1) | TWI260986B (https=) |
| WO (1) | WO2000016797A2 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US7259136B2 (en) | 1999-04-30 | 2007-08-21 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating peripheral vascular disease |
| US6284725B1 (en) † | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
| US6429197B1 (en) * | 1998-10-08 | 2002-08-06 | Bionebraska, Inc. | Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
| EP2206720A1 (en) | 2000-04-12 | 2010-07-14 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| JP2003532691A (ja) * | 2000-05-05 | 2003-11-05 | ノボ ノルディスク アクティーゼルスカブ | 重症疾患神経障害 |
| ATE397938T1 (de) | 2000-05-19 | 2008-07-15 | Amylin Pharmaceuticals Inc | Behandlung des akuten koronaren syndroms mit glp- 1 |
| EP1411968B1 (en) | 2001-07-31 | 2008-09-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Glp-1 exendin-4 peptide analogs and uses thereof |
| US20040235726A1 (en) * | 2001-10-01 | 2004-11-25 | Jakubowski Joseph Anthony | Glucagon-like peptides (glp-1) and treatment of respiratory distress |
| EP2261250B1 (en) | 2001-12-21 | 2015-07-01 | Human Genome Sciences, Inc. | GCSF-Albumin fusion proteins |
| US20030199445A1 (en) | 2002-02-07 | 2003-10-23 | Knudsen Lotte Bjerre | Use of GLP-1 compound for treatment of critically ill patients |
| CN1332711C (zh) | 2002-02-20 | 2007-08-22 | 埃米球科技有限公司 | 施用glp－1分子的方法 |
| CA2513213C (en) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| MXPA05013565A (es) | 2003-06-12 | 2006-03-09 | Lilly Co Eli | Proteinas de fusion analogas al glp-1. |
| MXPA06006745A (es) | 2003-12-18 | 2006-08-18 | Novo Nordisk As | Compuestos glp-1 novedosos. |
| US20060286129A1 (en) | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
| ES2567634T3 (es) | 2004-02-09 | 2016-04-25 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina |
| PT1881850E (pt) | 2005-05-13 | 2010-11-26 | Lilly Co Eli | Compostos peguilados de glp-1 |
| MX2008001468A (es) | 2005-06-30 | 2008-04-07 | Sod Conseils Rech Applic | Composiciones farmaceuticas del peptido similar al glucagon-1. |
| CA2727147A1 (en) | 2008-06-17 | 2009-12-23 | Otsuka Chemical Co., Ltd. | Glycosylated glp-1 peptide |
| EP2216042A1 (en) | 2009-02-09 | 2010-08-11 | Ipsen Pharma S.A.S. | GLP-1 analogues pharmaceutical compositions |
| US8614185B2 (en) | 2009-05-04 | 2013-12-24 | Centocor Ortho Biotech Inc. | Fusion proteins of alpha-MSH derivatives and Fc |
| EP2427204B1 (en) | 2009-05-06 | 2017-04-05 | Janssen Biotech, Inc. | Melanocortin receptor binding conjugates |
| AU2010312655A1 (en) | 2009-10-30 | 2012-05-03 | Glytech, Inc. | Glycosylated form of antigenic GLP-1 analogue |
| EP2512518A1 (en) | 2009-12-16 | 2012-10-24 | Novo Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
| RU2013103763A (ru) | 2010-07-02 | 2014-08-10 | Ангиохем Инк. | Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения |
| EP2637698B1 (en) * | 2010-11-09 | 2022-04-20 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| RU2602601C2 (ru) | 2011-04-12 | 2016-11-20 | Ново Нордиск А/С | Дважды ацилированные производные glp-1 |
| CN104203266B (zh) | 2012-03-22 | 2017-12-26 | 诺和诺德股份有限公司 | Glp‑1肽组合物及其制备 |
| DK2827845T3 (en) | 2012-03-22 | 2019-04-01 | Novo Nordisk As | COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF |
| JP6517690B2 (ja) | 2012-06-20 | 2019-05-22 | ノヴォ ノルディスク アー／エス | ペプチド及び送達剤を含む錠剤製剤 |
| JP6672140B2 (ja) | 2013-05-02 | 2020-03-25 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１化合物の経口投薬 |
| EP3019184A4 (en) * | 2013-06-07 | 2017-04-05 | The Administrators of the Tulane Educational Fund | Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use |
| CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
| KR101825048B1 (ko) | 2014-12-31 | 2018-02-05 | 주식회사 제넥신 | GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도 |
| PL3257524T3 (pl) | 2015-02-11 | 2021-03-08 | Gmax Biopharm Llc | Stabilny preparat farmaceutyczny w postaci roztworu białka fuzyjnego przeciwciała przeciwko glp-1r |
| CN105254720B (zh) * | 2015-11-18 | 2018-10-09 | 暨南大学 | 一种多受体激动剂po13及应用 |
| WO2018113340A1 (zh) * | 2016-12-20 | 2018-06-28 | 中国药科大学 | 多肽p11及其用途 |
| PL3746111T3 (pl) | 2018-02-02 | 2024-01-15 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową |
| CN117003874A (zh) | 2018-03-20 | 2023-11-07 | 鸿运华宁（杭州）生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| CN112521501A (zh) | 2019-09-18 | 2021-03-19 | 鸿运华宁（杭州）生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| EP4090351B1 (en) * | 2020-01-16 | 2026-03-04 | Shanghai Benemae Pharmaceutical Corporation | Dosing regimen of glp-1 |
| US20240050531A1 (en) * | 2020-12-16 | 2024-02-15 | The Chinese University Of Hong Kong | A method for reversing aging brain functional decline |
| CN116970062B (zh) * | 2022-04-29 | 2024-04-09 | 南京知和医药科技有限公司 | 一种超长效glp-1多肽衍生物及其制备方法和用途 |
| CN120037358A (zh) * | 2022-06-23 | 2025-05-27 | 广州银诺医药集团股份有限公司 | 一种改进的glp-1受体激动剂的融合蛋白的联合疗法 |
| JP2025531814A (ja) | 2022-09-08 | 2025-09-25 | ジーマックス バイオファーム エルエルシー | Ｇｉｐｒ抗体、ｆｇｆ２１との融合タンパク質、その医薬組成物及びその使用 |
| CN119569847A (zh) * | 2024-12-03 | 2025-03-07 | 中国科学院上海有机化学研究所 | Glp-1变体及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK36392D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
| IL128332A0 (en) * | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| US6006753A (en) * | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
| US6277819B1 (en) * | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
| JP2001525371A (ja) * | 1997-12-05 | 2001-12-11 | イーライ・リリー・アンド・カンパニー | Ｇｌｐ−１製剤 |
-
1999
- 1999-09-21 MY MYPI99004103A patent/MY155270A/en unknown
- 1999-09-22 EP EP99951570A patent/EP1115421B1/en not_active Expired - Lifetime
- 1999-09-22 DE DE69940975T patent/DE69940975D1/de not_active Expired - Lifetime
- 1999-09-22 AT AT99951570T patent/ATE433324T1/de not_active IP Right Cessation
- 1999-09-22 JP JP2000573758A patent/JP2002526454A/ja active Pending
- 1999-09-22 CN CNB998113077A patent/CN1163267C/zh not_active Expired - Fee Related
- 1999-09-22 WO PCT/US1999/022026 patent/WO2000016797A2/en not_active Ceased
- 1999-09-22 BR BR9913932-4A patent/BR9913932A/pt not_active Application Discontinuation
- 1999-09-22 CA CA002344056A patent/CA2344056A1/en not_active Abandoned
- 1999-09-22 ES ES99951570T patent/ES2325777T3/es not_active Expired - Lifetime
- 1999-09-22 AU AU63985/99A patent/AU766375B2/en not_active Ceased
- 1999-10-20 TW TW088116396A patent/TWI260986B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2325777T3 (es) | 2009-09-16 |
| EP1115421A2 (en) | 2001-07-18 |
| WO2000016797A2 (en) | 2000-03-30 |
| ATE433324T1 (de) | 2009-06-15 |
| BR9913932A (pt) | 2001-10-16 |
| AU766375B2 (en) | 2003-10-16 |
| AU6398599A (en) | 2000-04-10 |
| EP1115421B1 (en) | 2009-06-10 |
| JP2002526454A (ja) | 2002-08-20 |
| CN1163267C (zh) | 2004-08-25 |
| CN1322137A (zh) | 2001-11-14 |
| TWI260986B (en) | 2006-09-01 |
| WO2000016797A3 (en) | 2000-05-25 |
| CA2344056A1 (en) | 2000-03-30 |
| DE69940975D1 (de) | 2009-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY155270A (en) | Use of glp-1 or analogs in treatment of stroke | |
| EP0964692A4 (en) | USE OF GLP-1 OR ANALOG IN THE TREATMENT OF MYOCARDIC INFARCT | |
| MY121276A (en) | Use of glp-1 or analogs to abolish catabolic changes after surgery | |
| EA200000747A1 (ru) | СПОСОБ ВВЕДЕНИЯ AspB28-ИНСУЛИНА ЧЕЛОВЕКА | |
| BE2018C038I2 (https=) | ||
| ZA967626B (en) | Lipid extract having anti-inflammatory activity. | |
| NZ514077A (en) | Treatment of Α-galactosidase A deficiency | |
| GR3036071T3 (en) | Use od moxonidine for the Treatment of neuropathic pain | |
| AU6432899A (en) | Use of metformin to counteract weight gain associated with valproate and other psychotropic medications | |
| NZ332690A (en) | Stimulation of host defence mechanisms against viral challenges using interferon | |
| EP1566180A3 (en) | Use of GLP-1 or Analogs in Treatment of Myocardial Infarction | |
| ES2110104T3 (es) | Procedimiento para la administracion de soluciones de factor de estimulacion de las colonias de granulocitos. | |
| AU1564500A (en) | Method for obtaining and using a combination of a purine and a nitrogen monoxidedonor for preventing or treating sexual dysfunction | |
| MD1469G2 (ro) | Metodă de tratament al şocului combustional | |
| SG49645A1 (en) | A method of treating liver disease and like indications with vasodilating agents | |
| IT1261863B (it) | Preparazioni farmaceutiche orali, a base di diltiazem, a cessione protratta e controllata, con le quali e' possibile adottare una sola somministrazione giornaliera. | |
| SE0000837D0 (sv) | New use | |
| AR023398A1 (es) | Terapia para melanomas | |
| AR006382A1 (es) | Procedimiento para el tratamiento del envejecimiento cutaneo y de lesiones atroficas mediante la administracion de una preparacion conteniendoacido hialuronico y/o hialuronatos. | |
| TH16764A (th) | การรักษาโรคเบาหวานโดยการให้ ไมโอ-ไอโนซิทอล |